Sign In
ALXN.US
id: 822, Created by Stan Vick, Scout

Alexion (ALXN) $125M Shareholder Settlement

Claim payout
D. Connecticut
Court
3:16-cv-2127
Case number
30 Jan 2014
Class period Start
26 May 2017
Class period End
Alexion (ALXN) agreed to settle a $125 million with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.76
Filing date
17 November 2016
Lead plaintiff
Boston Retirement System, David A. Slossberg, Jeffrey P. Nichols
Attorney
Labaton Sucharow LLP, Motley Rice LLC, Sturman LLC, Risch Pisca LLC
Defendants
Leonard Bell, David L. Hallal, Vikas Sinha
Judge
Hon. Alvin W. Thompson
Settlement agreement date
2023-09-13
Trades matching type
FIFO
+$125,000,000
Total Settlement Amount
Created by Stan Vick, Scout

Case history

Stan Vick
16 September 2023
  • Alexion shareholders asked approval from a federal judge in Connecticut for a $125 million settlement.
  • This deal aims to resolve allegations that $ALXN allegedly illegal sales strategy led to a significant drop in stock price.
Stan Vick
18 September 2023
$ALXN case-related News:
In a New York federal court, a former vice president of Alexion Pharmaceuticals Inc. entered a guilty plea for informing a childhood friend about the $ALXN $1.4 billion acquisition of another biotech firm in 2020.

Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemo...

    Ticker
    ALXN.US
    ISIN
    US0153511094
    CIK
    899866
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    121 Seaport Boulevard, Boston, MA, United States, 02210